



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Thomas Gruber
Appl. No.: 10/772,647
Conf. No.: 5813
Filed: February 4, 2004
Title: PHARMACEUTICAL FORMULATION CONTAINING DYE
Art Unit: 1615
Examiner: Unknown
Docket No.: 111458-004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 37 C.F.R. 1.97, and 37 C.F.R. 1.98, Applicants request that a citation and examination of the references cited below, and on the attached PTO-1449 form, be made during the course of examination of the above-identified application for United States patent. Pursuant to the Official Gazette Notice dated August 5, 2003, copies of the cited U.S. patents and patent applications are not included as this application was filed after June 30, 2003. However, copies of all other cited references are included with this form.

U.S. PATENT DOCUMENTS

<u>Document No.</u>	<u>Date</u>	<u>Inventor</u>
3,980,766	September 14, 1976	Shaw et al.
4,769,372	September 6, 1988	Kreek
4,785,000	November 15, 1988	Kreek et al.
5,266,331	November 30, 1993	Oshlack et al.
5,472,943	December 5, 1995	Crain et al.
5,508,042	April 16, 1996	Oshlack et al.
5,549,912	August 27, 1996	Oshlack et al.
5,656,295	August 12, 1997	Oshlack et al.
6,228,863	May 8, 2001	Palermo et al.
6,245,357	June 12, 2001	Edgren et al.

FOREIGN PATENT DOCUMENTS

<u>Document No.</u>	<u>Date</u>	<u>Country</u>
WO 99/32119	July 1, 1999	PCT

Applicants look forward to early and favorable consideration of this matter.

Respectfully submitted,

BELL, BOYD & LLOYD LLC

BY 

Adam H. Masia


Reg. No.35,602

P.O. Box 1135

Chicago, Illinois 60690-1135

Phone: (312) 807-4284

Dated: June 8, 2004



**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**
(Use several sheets if necessary)

PTO Form 1449

Atty Docket No.
111458

Application No.
10/772,647

Applicant
Thomas Gruber

Filing Date
February 4, 2004

Group
1615

U.S. PATENT DOCUMENTS

Examiner's Initials	Document Number	Publication Date	Inventor	Class	Subclass	Filing Date If Appropriate
	3,980,766	September 14, 1976	Shaw et al.			
	4,769,372	September 6, 1988	Kreek			
	4,785,000	November 15, 1988	Kreek et al.			
	5,266,331	November 30, 1993	Oshlack et al.			
	5,472,943	December 5, 1995	Crain et al.			
	5,508,042	April 16, 1996	Oshlack et al.			
	5,549,912	August 27, 1996	Oshlack et al.			
	5,656,295	August 12, 1997	Oshlack et al.			
	6,228,863	May 8, 2001	Palermo et al.			
	6,245,357	June 12, 2001	Edgren et al.			

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Document Number	Publication Date	Country	Class	Subclass	Translation	
						Yes	No
	WO 99/32119	July 1, 1999	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner's Initials	

Examiner:

Date Considered:


*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

IFW

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
111458-004

In Re Application Of: Thomas Gruber



Serial No.
10/772,647

Filing Date
February 4, 2004

Examiner
Unknown

Group Art Unit
1615

Title: **PHARMACEUTICAL FORMULATION CONTAINING DYE**

Address to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
111458-004

In Re Application: Thomas Gruber

Serial No.
10/772,647

Filing Date
February 4, 2004

Examiner
Unknown

Group Art Unit
1615

PHARMACEUTICAL FORMULATION CONTAINING DYE

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 02-1818 as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☐ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F:

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on June 8, 2004 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature of Person Mailing Correspondence

Renee Street

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Signature

Dated: June 8, 2004

Adam H. Masia
Reg. No. 35,602
BELL, BOYD & LLOYD LLC
P.O. Box 1135
Chicago, Illinois 60690-1135
Phone: (312) 807-4284

CC: